January 27, 2016 – TARRYTOWN, N.Y., – PsychoGenics announced today that it has obtained a license from University of California, San Diego to its Line-41 mouse model of Alzheimer’s disease, expressing human APP with the Swedish (K670N/M671L) and London (V717I) mutations under the control of the murine-Thy-1 promoter.